According to the expression characteristics of CD20 in the B lymphocyte development stage, it has been selected as one of the targets for the treatment of B-cell lymphoma, and many antibody drugs have been successfully developed based on this target [10]. Here, MS4A1 is linked to B-cell non-Hodgkin lymphoma.